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Epigenetic mechanisms are an important heritable and dynamic means of regulating various 
genomic functions, including gene expression, to orchestrate brain development, adult 
neurogenesis, and synaptic plasticity. These processes when perturbed are thought to contribute 
to schizophrenia pathophysiology. A core feature of schizophrenia is cognitive dysfunction. For 
genetic disorders where cognitive impairment is more severe such as intellectual disability, there 
are a disproportionally high number of genes involved in the epigenetic regulation of gene 
transcription. Evidence now supports some shared genetic aetiology between schizophrenia and 
intellectual disability. GWAS have identiﬁed 108 chromosomal regions associated with 
schizophrenia risk that span 350 genes. This study identiﬁed genes mapping to those loci that have 
epigenetic functions, and tested the risk alleles deﬁning those loci for association with cognitive 
deﬁcits. We developed a list of 350 genes with epigenetic functions and cross-referenced this with 
the GWAS loci. This identiﬁed eight candidate genes: BCL11B, CHD7, EP300, EPC2, GATAD2A, 
KDM3B, RERE, SATB2.Usinga dataset of Irish psychosis cases and controls (n ¼ 1235), the 
schizophrenia risk SNPs at these loci were tested for effects on IQ, working memory, episodic 
memory, and attention. Strongest associations were for rs6984242 with both measures of IQ (P ¼ 
0.001) and episodic memory (P ¼ 0.007). We link rs6984242 to CHD7 via a long range eQTL. These 
associations were not replicated in independent samples. Our study highlights that a number of 
genes mapping to risk loci for schizophrenia may function as epigenetic 
INTRODUCTION 
Epigenetic mechanisms are heritable and have an important role in the dynamic regulation of 
various genomic functions, including gene expression. This is largely achieved through the covalent 
modiﬁcation of DNA and histones. Epigenetic chromatin modiﬁcations establish and maintain gene 
expression programs to help orchestrate brain development, adult neurogenesis, and synaptic 
plasticity [Qureshi and Mehler, 2013], processes that when perturbed are thought to contribute to 
the pathophysiology of schizophrenia [Liu et al., 2014; Wockner et al., 2014]. Recent exome 
sequencing [McCarthy et al., 2014; Takata et al., 2014] has identiﬁed rare mutations in genes 
associated with epigenetic chromatin remodeling in schizophrenia. Pathway analysis of genome-
wide association study (GWAS) data have supported a role for epigenetic mechanisms (histone 
methylation) in major psychiatric disorders [O’Dushlaine, 2015]. 
A core feature of schizophrenia is cognitive dysfunction in the form of impairments in memory, 
attention and IQ. This has a genetic basis and decline in cognitive performance occurs years prior to 
onset of illness as the brain is still developing [Kahn and Keefe, 2013]. For genetic disorders where 
cognitive impairment is more severe than in schizophrenia such as intellectual disability, there are a 
disproportionally high number of genes involved in the epigenetic regulation of gene transcription 
[Kleefstra et al., 2014]. Loss-of-function (LoF) mutations in the MECP2 gene (encoding a methyl-DNA 
binding protein) causing Rett syndrome is the classic example of an “epigenetic gene” being mutated 
to cause a disorder with severe cognitive deﬁcits. There are currently >50 genes identiﬁed that 
function in different epigenetic mechanisms and are mutated in cognitive disorders [Kleefstra et al., 
2014]. Evidence now supports some shared genetic aetiology between schizophrenia and 
intellectual disability [Fromer et al., 2014]. Therefore, it is pertinent to ask if an overlapping 
phenotypic characteristic of schizophrenia and intellectual disability (cognitive deﬁcits) could be due 
to genetic variability in a shared pathobiology (epigenetic mechanisms). 
A meta-analysis of over 50 GWAS studies performed by the Psychiatric Genomics Consortium (PGC) 
has culminated in the identiﬁcation of 108 risk loci for schizophrenia that contain some 350 genes 
[Schizophrenia Working Group of the Psychiatric Genomics, 2014]. Our study asks: do any genes at 
these new schizophrenia risk loci regulate epigenetic mechanisms, speciﬁcally as chromatin 
modulators of gene expression? For those loci containing those genes, we next ask whether they 
independently associate with cognitive functions? Our overall hypothesis is that GWAS-identiﬁed 
risk genes for schizophrenia, which regulate epigenetic mechanisms, are associated with deﬁcits in 
cognitive function. 
MATERIALS AND METHODS 
Chromatin Modulators 
We prepared a list of genes encoding the major classes of chromatin modulators which 
encompasses epigenetic regulators of gene expression (Table I). Relevant genes were collected from 
two of the main online gene databases; Gene Cards (http://www. genecards.org/) and the Gene 
Ontology Consortium (http://geneontology.org/) as follows: Searches of these databases were 
conducted using speciﬁc keywords to distinguish the type of chromatin modulation that was being 
investigated. For example, in the case of Genecards, a human gene database, we used the advanced 
search option (http://www.genecards.org/Search) using terms such as “histone AND 
acetyltransferase” to search the summaries section. In the case of Gene Ontology we searched the 
ontology database (http://amigo2.berkeleybop.org/amigo/search/ontology) using terms such as 
“histone acetylation” giving the branch “GO:0016573 histone acetylation” under inferred tree view, 
following the “link to all genes and gene products annotated,” ﬁltering with the term “Homo 
sapiens” returns a list of relevant genes. In addition to using these two databases, in the case of 
histone ubiquitination we have included the full list of E1 ubiquitin activating enzymes, and E2 
ubiquitin conjugating enzymes as it is not always known which of these coordinates with the E3 
ubiquitin ligase enzyme to mediate the modiﬁcation. This list was selected from the list compiled by 
Van Wijk and Timmers [2010]. The two lists for the same chromatin modulation were combined, 
duplicate entries were removed and each gene was then manually queried for legitimate inclusion. 
At this point an associated list was appended onto the list of known modulators, this includes factors 
that exist in complex with the enzyme in question, and are required for its activity (Supplementary 
Table SI). Also shown in the list are the target residues/histone of the enzyme where known, and a 
brief statement of evidence as taken from Genecards’ summary section, which summarizes gene 
function from Entrez Gene, UniProtKB (UniprotKB/Swiss-Prot/UniprotKB/TrEMBL), Tocris Bioscience, 
PharmGKB, and Gene Wiki. These genes were assembled into a ﬁnal list of 350 unique chromatin-
modulating genes (Supplementary Table SI), which from here on we refer to as “epigenetic genes.” 
The epigenetic gene list (n ¼ 350) was cross-referenced with genes located in 108 chromosomal 
regions associated with schizophrenia risk (n ¼ 350) [Schizophrenia Working Group of the Psychiatric 
Genomics, 2014] to identify candidate genes for this study. 
 
Study Participants and Neuropsychological 
Testing 
This study used an Irish dataset of broad psychosis cases (n ¼ 890) and controls (n ¼ 330) who had 
completed tests in ﬁve main areas of cognition and for whom GWAS data were available. Cases were 
clinically stable patients with a DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th 
Edition) diagnosis of schizophrenia (n ¼ 559), schizoaffective disorder (n ¼ 111), bipolar disorder (n ¼ 
148), major depressive disorder with psychotic features (n ¼ 38), or psychosis not otherwise 
speciﬁed (n ¼ 34) recruited from ﬁve sites across Ireland (Table II). Inclusion criteria required that 
participants were clinically stable at the time of neuropsychlogical testing, were aged 18–65 years, 
had no history of comorbid psychiatric disorder, no reported substance abuse in the preceding 6 
months, no prior head injury with loss of consciousness, and no history of seizures. Diagnosis was 
conﬁrmed by trained psychiatrists using the Structured Clinical Interview for DSM-IV-TR [First et al., 
2002]. A more detailed description of sample ascertainment has previously been published 
[Cummings et al., 2013]. Healthy control participants were recruited via online and poster 
advertising. They were aged 18–65 years, with no reported history of substance abuse in the 
preceding 6 months, no prior head injury with loss of consciousness, no history of seizures, and no 
personal history of psychosis or in their ﬁrst-degree relatives. All assessments were conducted in 
accordance with the relevant ethics committees’ approval from each participating site. All 
participants had four grandparents born in Ireland and provided written informed consent. 
Participants completed a neuropsychological assessment battery designed to target the cognitive 
deﬁcits observed in schizophrenia, this battery included general cognitive function, episodic 
memory, working memory, and attentional control. General cognitive functioning (IQ) was measured 
using selected subtests (Vocabulary, Similarities, Block Design, and Matrix Reasoning) from the 
Wechsler Adult Intelligence Scale (WAIS); [Weschler, 1997a, 2001] which assessed verbal, 
performance, and full-scale IQ as well as the Wechsler Test of Adult Reading (WTAR). Episodic 
memory was assessed using the logical memory (LM) 1 and 2 tasks as well as the “Faces 1 and 2” 
task subtests from the Wechsler Memory Scale (WMS) III [Weschler, 1997b] as well as the Paired-
Associates Learning task (PAL). Working memory was assessed using the spatial working memory 
task (SWM) from the Cambridge Neuropsychological Test Automated Battery (CANTAB) [Robbins et 
al., 1994] and letter-number sequencing from the WMS III [Weschler, 1997b]. Attentional control 
was assessed using the Continuous Performance Task (CPT)—Identical Pairs version, and the 
Sustained Attention to Response Task [Cornblatt et al., 1988; Robertson, 1994]. 
Genotyping and Statistical Analysis 
Genotyping was conducted on DNA extracted from blood or saliva from patient and control 
participants. SNP data were obtained from two different sites; a recent GWAS using the Affymetrix 
SNP Array 6.0 platform, conducted as part of the Wellcome Trust Case Control Consortium 2 [Irish 
Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2, 2012] and 
a collaborative GWAS with Cardiff University using an Illumina Human Core Exome (þcustom) SNP 
array. Full GWAS data on these samples included recently completed imputation using 1000 
Genomes Phase I data and IMPUTE2 [Howie et al., 2009] to give ฀10 million SNPs genome-wide per 
sample. Only samples that had passed the quality control ﬁltering were imputed using the 1000 
Genomes reference panel. Imputed data were converted to best guess genotypes using PLINK 
[Purcell et al., 2007], which was also used to extract data on the index SNP at each gene from GWAS 
data and combine it in Statistical Package for the Social Sciences (SPSS) 21, IBM) with data from an 
extensive neuropsychological battery. Statistical analysis was carried out in SPSS using a linear-based 
model of regression. Because of differences in cognitive scores between male and female 
participants and between older and younger individuals, gender and the age at the time of 
assessment were used as co-variate measures to determine a general genotype effect across all 
cases and controls. Cognitive test scores for each genotype group were compared using a three 
group analysis, that is, homozygous non-risk versus heterozygous versus homozygous risk genotype 
groups. R2 is a measure of how close the data ﬁts to the regression line. R2 change values were used 
in this analysis which identiﬁes changes in the original R2 based on the linear contribution of 
variables added into the regression model. Regarding power in this sample, which in itself is too 
small for GWAS, to detect for example, differences in Performance IQ for a SNP where the mean 
difference in scores between risk allele carriers and non-carriers was 0.5 standard deviations (SD), 
our sample had 87% power at a ¼ 0.05. For a mean difference of 0.33 or 0.75 SD, the power was 
59% and 99%, respectively for the same type I error rate. 
 
  
Interaction Analysis 
Online tools and resources including STRING (http://string-db. org/) and the ingenuity pathway 
analysis (IPA) database (http://www.ingenuity.com/) were used to identify direct (physical bind-ing) 
and indirect (functional) interacting partners of each candidate gene based on genomic and co-
expression data as well as experimental data from literature searches. Gene IDs from each 
interaction network were compiled into lists and cross-referenced with the epigenetic gene list (n ¼ 
350) and the GWAS schizophrenia gene list (n ¼ 350) to determine if any interacting partners had 
epigenetic functions and were associated with schizophrenia risk. Among the candidate genes, three 
pairs of genes were identiﬁed as interacting partners: SATB2 and BCL11B, EP300 and BCL11B, and 
CHD7 and GATAD2A. All three combinations were taken forward for neuropsychological interaction 
analysis using the same Irish dataset. Interaction analysis was carried out in SPSS based on a linear 
model of regression using up to ﬁve genotype groups where study participants were assigned to 
groups based on the number of schizophrenia risk alleles they carried at the two SNPs from a pair of 
interacting genes. Gender and age at time of assessment were used as co-variate measures in this 
analysis. 
UK Replication Sample 
About 772 individuals with schizophrenia or schizoaffective dis-order—depressive subtype were 
recruited from community mental health teams in Wales and England. The Schedule for Clinical 
Assessment in Neuropsychiatry (SCAN) interview was conducted followed by case note review and 
consensus diagnosis according to DSM-IV criteria. Individuals were assessed using the Measurement 
and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive 
Battery (MCCB). The MCCB is a 10 test cognitive battery consisting of seven cognitive domains: 
speed of processing, attention and vigilance, working memory, verbal learning, visual learning, 
reasoning and problem solving, and social cognition [Nuechterlein et al., 2008]. These domains were 
chosen as primary cognitive outcomes given that the MATRICS tests were selected on the basis of 
the domains they measured, and the fact that this approach minimized measurement error as some 
domains are assessed by more than one test. Allinterviewers were trained in the use of the SCAN 
interview and MCCB. The UK Multicentre Research Ethics Committee (MREC) approved the study 
and all participants provided valid informed consent. These samples were genotyped at the Broad 
Institute, Massachusetts on the Illumina HumanOmniExpressExome-8v1. QC procedures followed 
those of the PGC [Schizophrenia Working Group of the Psychiatric Genomics, 2014]. Imputation was 
carried out by the PGC using IMPUTE2 and for this analysis we converted imputed to best guess 
genotypes using PLINK [Purcell et al., 2007; Howie et al., 2009]. 
German Replication Sample 
Patients with a DSM-IV diagnosis of schizophrenia were ascertained from mental health services in 
the Munich area. Exclusion criteria were a history of head injury or neurological disease. Patients, 
ages 18–80 years, were interviewed with the Structured Clinical Interview for DSM-IV (SCID), and the 
interviews were rated by psychiatrists or psychologists. Healthy comparison sub-jects of German 
descent, ages 18–80 years, were randomly selected from population registers from the Munich area. 
Participants underwent an extensive screening process to exclude those with neurological or 
psychotic disorders and those who had ﬁrst-degree relatives with psychotic disorders. In the case of 
participants older than 60 years, the Mini-Mental State Examination was employed to exclude 
individuals with possible cognitive impairment [Walters et al., 2013]. In this sample, IQ was 
measured by the full German Wechsler Adult Intelligence Scale—Revised (WAIS-R). Episodic memory 
was assessed using the immediate and delayed logical memory tests from the German Wechsler 
Memory Scale—Revised (WMS-R) [H€arting et al., 2000]. For Full Scale IQ and Verbal IQ, data were 
available for 355 patients and 2,147 healthy comparison subjects. For Episodic Memory, data were 
available for 362 patients and 558 healthy comparison subjects. GWAS data were available for these 
samples. Individuals were genotyped on different plat-forms and imputed in six batches. Quality 
control and imputation of batches 1 (Human610-Quadv1_B, Human660W-Quad_v1_A, Human610-
Quadv1_B), 2 (HumanHap 300 v1.0.0), and 3 (Affymetrix 6.0) were performed in the framework of 
the PGC2 schizophrenia meta-analysis [Schizophrenia Working Group of the Psychiatric Genomics, 
2014]. Batches 4 (HumanHap 300 v1.0.0), 5 (Illumina Human OmniExpress 12v1.0), and 6 (Illumina 
Omni1-Quad) were imputed following the same QC and imputation protocols with minor 
adaptations. Sample call-rate was adjusted to account for smaller sample sizes with a minimum 
threshold of 96%. After imputation the batches were combined and all markers that differed more 
than 0.1 in minor allele frequency between any of the batches were excluded. Association analysis 
was done with PLINK using a linear regression model corrected for age, sex, education, affection 
status and batch. 
RESULTS 
The PGC GWAS identiﬁed SNPs associated with SZ in 108 loci that contain 350 genes [Schizophrenia 
Working Group of the Psychiatric Genomics, 2014]. Cross referencing our list of chromatin 
modulators with the genes in the GWAS schizophrenia risk loci identiﬁed a shortlist of 17 epigenetic 
genes in schizophrenia risk regions. As some of the risk loci include large numbers of genes, we 
systematically reviewed each GWAS results plot to conservatively reduce our gene list to seven 
genes (BCL11B, EP300, EPC2, GATAD2A, KDM3B, RERE, and SATB2), where the associated SNP is 
located within or close to the gene location. Three of these genes, BCL11B, EPC2, and SATB2, are the 
only gene within their associated locus. For the remaining four genes, positional and linkage 
disequilibrium evidence from the relevant plots was strong enough to suggest that they could be 
affected by the risk SNPs at these loci. 
We also considered the possibility that a risk SNP may affect a gene outside its risk region. In the 
schizophrenia GWAS it is worth noting that there are 21 loci that do not contain any genes. To 
identify such distantly affected genes, we took advantage of a recent genome-wide brain expression 
quantitative trait loci (eQTL) study [Kim et al., 2014]. This study reports results for eQTL analysis 
between SNPs and the expression of genes within 1 Mb of the SNP (i.e., a 2 Mb window). We 
extracted the eQTL results for all 128 schizophrenia index risk SNPs reported by the PGC and found 
that 59 SNPs had an eQTL at nominal P < 0.05. For each of these SNPs we calculated the number of 
genes within the 2 Mb window and Bonferroni corrected for that number of genes at each SNP 
[Dunn, 1961]. This identiﬁed 16 unique SNPs with signiﬁcant eQTL results that totalled 21 genes 
(Supplementary Table SII). We cross-referenced these 21 genes with our epigenetic gene list and 
identiﬁed one extra gene for study, CHD7. For each candidate gene, the highest associated SNP (the 
index SNP from the GWAS region containing that gene) was used for analysis of neuropsychological 
variables. 
The ﬁnal eight genes (with corresponding index SNPs) for analysis are listed here including brief 
details of function and descriptions of any cognitive disorders caused by these genes: 
(1) BCL11B (rs2693698) encodes B-Cell CLL/Lymphoma 11B, a protein associated with the Mi-
2/nucleosome remodelling and deacetylase complex (NuRD) [Cismasiu et al., 2005]. 
(2) CHD7 (rs6984242) encoding chromodomain helicase DNA binding protein 7, is an ATP-
dependent chromatin remodeller. De novo mutations in CHD7 cause Charge syndrome, a disorder 
characterized by abnormal ear formation, hearing loss, cleft palate, coloboma, genital hypoplasia, 
delayed development, and intellectual disability [Lalani et al., 2006]. De novo mutations in CHD7 
have also been found in cases of autism [O’Roak et al., 2012b; Jiang et al., 2013] and CHD7 has been 
shown to interact directly and indirectly with CHD8, a conﬁrmed risk gene for autism [Batsukh et al., 
2010; Wilkinson et al., 2015]. 
(3) EP300 (rs9607782) encodes the histone acetyltransferase, E1A Binding Protein P300. De 
novo mutations within the EP300 gene cause rare cases of Rubinstein–Taybi syndrome, a disorder 
characterized by intellectual disability and developmental abnormalities [Negri et al., 2014]. 
(4) EPC2 (rs200327371) encodes Enhancer Of Polycomb Homo-log 2, protein associated with a 
chromatin repressive complex. Microdeletions within the 2q23.1 region containing EPC2 are 
associated with intellectual disability, seizures, microcephaly, development delay, hypotonia, and 
behavioral features similar to autism or Angelman syndrome [Van Bon et al., 2010]. 
(5) KDM3B (rs10043984), Lysine (K)-Speciﬁc Demethylase 3B is required for normal 
spermatogenesis and sexual behaviors in male mice [Liu et al., 2015] and encodes an enzyme that 
removes a key transcriptional repressive modiﬁcation from chromatin [Kim et al., 2012]. Levels of 
this histone modiﬁcation correlates with symptom severity in schizophrenia in a sex-speciﬁc manner 
[Chase et al., 2015]. 
(6) GATAD2A (rs2905426) is a transcriptional repressor and subunit of the NuRD complex [Wade 
et al., 1999; Brackertz et al., 2002]. 
(7) RERE (rs34269918) is a transcriptional co-repressor that binds chromatin and in mouse is 
involved in cerebellar development [Kim and Scott, 2014]. 
(8) SATB2 (rs6704641) encodes a protein involved in chromatin remodelling. De novo structural 
and point mutations in SATB2 result in SATB2 haploinsufﬁciency and a deﬁned SATB2 phenotype 
with developmental delay, mild to severe intellectual disability, behavioral problems and abnormal 
craniofacial features, speciﬁcally a cleft palate [Docker et al., 2014]. 
 
Each of the eight schizophrenia risk variants was analyzed against four areas of cognitive function 
(IQ, working memory, episodic memory, and attentional control). To maximize power, this was done 
in the combined sample of psychosis cases and controls. Table III highlights all nominally signiﬁcant 
associations detected. The strongest results were for rs6984242 (CHD7) where one association 
survives Bonferroni correction for the four cognitive domains tested and the eight variants tested 
(corrected P-value threshold ¼ 0.002). For that association, the schizophrenia risk allele (G) was 
associated with lower Verbal IQ (P ¼ 0.001) where an R2 change value of 0.010 indicates that 1.0% 
of the variance in test performance is explained by the genotype. The same variant was associated 
with two other measures of IQ (Full Scale IQ, P ¼ 0.007, and WTAR, P ¼ 0.003), as well as four 
measures of episodic memory function with the strongest result for the Faces task, delayed 
condition (P ¼ 0.007). 
Of the remaining seven variants, four variants (at EP300, GATAD2A, KDM3B, and RERE) had 
nominally signiﬁcant associations with at least one cognitive task (Table III). Of note, the risk allele 
for rs2905426 (GATAD2A, which interacts with CHD7) was also associated with lower Full Scale IQ (P 
¼ 0.016). To follow this up we performed an interaction analysis using the data for the variants at 
CHD7 and GATAD2A. In this regression analysis participants were categorized into four groups on the 
basis of the number of risk alleles they carried (0, 1, 2, or 3/4 [few participants carried four risk 
alleles so these individuals were grouped with those that carried three risk alleles]). Association was 
found with four measures of IQ (Table IV): Full Scale IQ (P ¼ 0.001), Verbal IQ (P ¼ 0.002), WTAR (P ¼ 
0.005), and Performance IQ (P ¼ 0.016). For Full Scale IQ, the R2 change value for the 2-SNP analysis 
was 0.013 whereas the R2 change value for rs6984242 (CHD7) on its own was 0.008. For Verbal IQ, 
the R2 change value for both the 
2-SNP and single SNP analysis is 0.010 and the range of mean scores for the 2-SNP and single SNP 
analysis largely overlap. For other nominally signiﬁcant associations from the 2-SNP analysis, the 
results do not differ much from the single SNP analysis. Thus, there is no strong evidence from this 
analysis that the effect from a genetic interaction between these two variants is contributing more 
signiﬁcantly to poorer cognitive performance than the individual variants on their own. Interaction 
analysis using the two other pairs of interacting partners identiﬁed (SATB2 and BCL11B,and EP300 
and BCL11B) did not detect any signiﬁcant associations. 
We sought independent replication of our Bonferroni-corrected signiﬁcant association between 
Verbal IQ and rs6984242 (CHD7). In doing these analyses, we also sought independent support for 
the associations we detected between this SNP and Full Scale IQ and with Episodic Memory. We 
used two independent datasets. The UK dataset is based on the MATRICS battery and so composite 
scores were used for cognitive domains. Similar to the Irish dataset, the German dataset used the 
WAIS to measure IQ and the WMS to measure Episodic Memory. rs6984242 did not show 
association with IQ or Episodic Memory in either dataset (Tables V and VI). 
 
  
DISCUSSION 
This study developed a list of 350 genes that function as chromatin modulators of gene expression. 
These genes were investigated for a role in cognitive deﬁcits in schizophrenia by ﬁrst determining 
which of these genes are present at loci that are genome-wide signiﬁcant for schizophrenia from the 
largest GWAS to date. The eight candidate schizophrenia risk genes identiﬁed had various epigenetic 
functions and a number are the site of causative mutations for rare cognitive disorders, for example, 
Charge syndrome (CHD7), Rubinstein–Taybi syndrome (EP300) and SATB2-associated syndrome. Five 
of the eight risk SNPs in question (rs6984242, rs2905426, rs9607782, rs10043984, and rs34269918) 
were found to be associated with poorer performance in tests from three of the four cognitive 
domains; IQ, episodic memory, and attention. For seven of the eight candidate genes, the 
schizophrenia risk SNP is located within or near the gene of interest. The impact of these variants on 
gene function is not certain. For three genes, there is brain eQTL data that identiﬁes the potential 
functional impact of SNPs on gene expression. Signiﬁcant eQTLs for rs9607782 and EP300, for 
rs6984242 and CHD7, and for rs2905426 and GATAD2A are reported in the Kim et al. [2014] brain 
eQTL data that included 424 brain samples. Finally, our extended analysis of this eQTL dataset 
identiﬁes CHD7 as a putative schizophrenia risk gene for the ﬁrst time. The index SNP in this instance 
is rs6984242 and the association signal from the GWAS maps to chr8:60,475,469–60,954,469(hg19), 
with the SNP located 891 Kb upstream of the ﬁrst exon of CHD7. There are only four genes within 
the 2 Mb region that centres on rs6984242 and CHD7 is the only gene with a signiﬁcant eQTL 
involving this SNP in the Kim et al. dataset. In an independent but much smaller brain eQTL dataset 
(n ¼ 134; www.braineac.org) the rs6984242-CHD7 eQTL is not supported by data from the 10 
different brain regions analyzed. CHD7 belongs to the chromodomain helicase DNA (CHD) binding 
family of proteins, where it is a member of subgroup III (along with CHD6, CHD8, and CHD9) based 
on sequence similarities and additional functional domains [Marfella and Imbalzano, 2007]. CHD 
genes are members of the SNF2 super-family of ATP-dependent chromatin remodelers [Flaus et al., 
2006; Marfella and Imbalzano, 2007] and function as part of large multisubunit complexes to 
regulate gene transcription, DNA repair, replication, and recombination. CHD7 interacts directly and 
indirectly with CHD8 [Batsukh et al., 2010], a gene that is recurrently mutated in autism [O’Roak et 
al., 2012a]. As brain eQTL and related functional datasets increase in size and power, we will seek 
more deﬁnite evidence to associate CHD7 with schizophrenia risk via rs6984242. 
 
 
 
 
It is rs6984242 that provides the strongest evidence of association where the schizophrenia risk 
allele (G) was associated with lower Verbal IQ (P ¼ 0.001) and explains 1.0% of the variance in test 
performance in our sample. This variant was also associated with other measures of IQ and episodic 
memory (P < 0.01). A combined analysis of rs6984242 with rs2905426 (at GATAD2A, known to 
interact with CHD7) also revealed a number of associations with IQ but the effect sizes did not point 
to an epistatic interaction between the two variants. Our analyses combined psychosis cases and 
healthy participants together to maximize sample size and power. When, in post hoc analyses, these 
samples were considered separately, the association between the risk allele at rs6984242 was not 
signiﬁcant in the healthy sample, but was marginally stronger in the case sample than for the sample 
as a whole (e.g., WTAR [P ¼ 0.004; R2 ¼ 0.013], Verbal IQ [P ¼ 0.002; R2 ¼ 0.012], Full Scale IQ ([P ¼ 
0.003; R2 ¼ 0.014], Faces 2 [P ¼ 0.009; R2 ¼ 0.013]). 
Our attempts to replicate signiﬁcant results were conservatively restricted to following up the 
associations between rs6984242 and IQ and episodic memory. We did not uncover independent 
data to support our associations in UK and German samples or in a combined meta-analysis (data 
not shown). Similarly, restricting the replication analyses to case-only samples did not uncover 
signiﬁcant results. There are a number of caveats to consider that could explain the non-replication. 
For the UK sample, comparable measures of general cognitive ability and memory were not 
available. In the German sample, where the same measures were available, the samples consisted 
mainly of healthy participants, for whom the association between rs6984242 and cognition was 
weaker in the Irish data. Finally, the modest though signiﬁcant amount of variance associated with 
rs6984242, which was estimated as being around 1%, may also suggest that the samples included 
here, though large for these types of studies, lacked power to detect association. 
Overall our study ﬁnds up to eight genes that function as chromatin modulators of gene expression 
and that map to loci that are associated with schizophrenia in the largest GWAS published to date. 
Rare mutations in a number of genes cause rare cognitive disorders. We found strong association 
between rs6984242, which we link to CHD7 via an eQTL, and measures of IQ and episodic memory in 
our dataset. However, we did not ﬁnd replicating evidence of association between this variant in 
independent datasets. Further eQTL, functional and behavioral studies will be required both to 
conﬁrm a link between rs6984242 and CHD7, thereby implicating this gene in schizophrenia biology, 
and to establish an association between this variant and cognition. 
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